<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001513'>Obesity</z:hpo>-associated low-grade systemic <z:mp ids='MP_0001845'>inflammation</z:mp> resulting from increased adipose mass is strongly related to the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> as well as other metabolic complications </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have demonstrated that the <z:mp ids='MP_0001261'>obese</z:mp> metabolic state can be improved by ablating certain inflammatory signaling pathways </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">Tumor progression</z:e> locus 2 (TPL2), a kinase that integrates signals from Toll receptors, cytokine receptors, and inhibitor of κ-B kinase-β is an important regulator of inflammatory pathways </plain></SENT>
<SENT sid="3" pm="."><plain>We used TPL2 knockout (KO) mice to investigate the role of TPL2 in mediating <z:hpo ids='HP_0001513'>obesity</z:hpo>-associated <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: Male TPL2KO and <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) littermates were fed a low-fat diet or a high-fat diet to investigate the effect of TPL2 deletion on <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:mp ids='MP_0001845'>inflammation</z:mp>, and insulin sensitivity </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We demonstrate that TPL2 deletion does not alter body <z:mp ids='MP_0005456'>weight gain</z:mp> or adipose depot weight </plain></SENT>
<SENT sid="6" pm="."><plain>However, hyperinsulinemic euglycemic clamp studies revealed improved insulin sensitivity with enhanced <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in skeletal muscle and increased suppression of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output in <z:mp ids='MP_0001261'>obese</z:mp> TPL2KO mice compared with <z:mp ids='MP_0001261'>obese</z:mp> WT mice </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with an improved metabolic phenotype, immune cell infiltration and <z:mp ids='MP_0001845'>inflammation</z:mp> was attenuated in the adipose tissue of <z:mp ids='MP_0001261'>obese</z:mp> TPL2KO mice coincident with reduced hepatic inflammatory gene expression and <z:chebi fb="23" ids="18059">lipid</z:chebi> accumulation </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Our results provide the first in vivo demonstration that TPL2 ablation attenuates <z:hpo ids='HP_0001513'>obesity</z:hpo>-associated metabolic dysfunction </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggest TPL2 is a novel target for improving the metabolic state associated with <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
</text></document>